Food supplements and diet as treatment options in irritable bowel syndrome

2020 ◽  
Vol 32 (8) ◽  
Author(s):  
Eirini Dimidi ◽  
Kevin Whelan
Keyword(s):  
Irritable Bowel Syndrome ◽  
Treatment Options ◽  
Food Supplements ◽  
Irritable Bowel

Irritable Bowel Syndrome with Diarrhea

2018 ◽  
Author(s):  
Judy Nee ◽  
Jacqueline L. Wolf
Keyword(s):  
Irritable Bowel Syndrome ◽  
Differential Diagnosis ◽  
Abdominal Pain ◽  
Treatment Options ◽  
Clinical Manifestations ◽  
Signs And Symptoms ◽  
Treatment Modalities ◽  
Dietary Advice ◽  
Emerging Therapies ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a complex, functional gastrointestinal condition characterized by abdominal pain and alteration in bowel habits without an organic cause. One of the subcategories of this disorder is IBS with diarrhea (IBS-D). Clinically, patients who present with more than 3 months of abdominal pain or discomfort associated with an increase in stool frequency and/or loose stool form are defined as having IBS-D. This review addresses IBS-D, detailing the epidemiology, etiology and genetics, pathophysiology and pathogenesis, diagnosis, clinical manifestations and physical examination findings, differential diagnosis, treatment, emerging therapies, complications, and prognosis. Figures show potential mechanisms and pathophysiology of IBS, IBS-D suspected by clinical assessment and Rome III criteria, pharmacologic and nonpharmacologic treatment options, potential mechanisms of action of probiotics, and potential treatment modalities. Tables list the Rome criteria for IBS, alarm signs and symptoms suggestive of alternative diagnoses, IBS criteria, differential diagnosis of IBS-D, dietary advice options for IBS-D, and alternative and emerging therapies in IBS-D. This review contains 5 figures, 6 tables and 42 references KEYWORDS: IBS-D, eluxadoline, rifaximin, probiotics, bloating, antidepressants, bile acid malabsorption, microscopic colitis, celiac

scholarly journals Socioeconomic Impact of Irritable Bowel Syndrome in Canada

2001 ◽  
Vol 15 (suppl b) ◽  
pp. 8B-11B ◽  
Author(s):  
Michel Boivin
Keyword(s):  
Health Care ◽  
Irritable Bowel Syndrome ◽  
Health Care Services ◽  
Financial Burden ◽  
Treatment Options ◽  
Indirect Costs ◽  
The United States ◽  
Physician Patient Relationship ◽  
Intangible Costs ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is the most common functional gastroenterological disorder reported to physicians. In Canada, its prevalence is about 6%. In the United States and the United Kingdom, the prevalence is estimated to be closer to 15%. Patients with IBS tend to make extensive use of health care services, even though a high percentage of them do not seek medical advice. The costs of IBS are a large expenditure of scarce resources. These costs can be divided into several categories: direct, indirect and intangible costs. The direct costs, associated with the diagnosis and treatment, are largely sustained by the health care system. The indirect costs are related to the production losses due to morbidity, and intangible costs are associated with the pain, suffering and alteration in the patient’s quality of life. The condition is a diagnosis of exclusion, and treatment, although beneficial, is rarely curative. The general treatment approach stresses the importance of a good physician-patient relationship. Exploring the nature of the expenses associated with IBS and understanding how treatment options may affect these costs are essential to reducing its financial burden.

Drug Treatment Options for Irritable Bowel Syndrome

Drugs & Aging ◽  
2001 ◽  
Vol 18 (3) ◽  
pp. 201-211 ◽  
Author(s):  
Rebecca C. Dunphy ◽  
G. Nicholas Verne
Keyword(s):  
Irritable Bowel Syndrome ◽  
Drug Treatment ◽  
Treatment Options ◽  
Irritable Bowel

scholarly journals Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea

2021 ◽  
Vol 11 ◽  
Author(s):  
Esther Colomier ◽  
Joost Algera ◽  
Chloé Melchior
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Pharmacological Treatment ◽  
Treatment Options ◽  
Treatment Algorithm ◽  
Gastrointestinal Symptoms ◽  
Bowel Habits ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is one of the most common disorders of the gut-brain axis, which affects approximately 4% of the global population. The Rome IV criteria define IBS as chronic or recurrent abdominal pain associated with altered bowel habits. Patients can be categorized in four subtypes: IBS with predominant constipation (IBS-C), predominant diarrhea (IBS-D), mixed bowel habits (IBS-M), and unclassified (IBS-U). IBS is associated with a lower quality of life, reduced work productivity, and high healthcare costs. When comparing subtypes, patients with IBS-D report lower disease related quality of life. Due to the scope of this review, we have solely focused on patients with IBS-D. Choosing the right pharmacological treatment in these patients remains challenging due to the heterogeneous patient population, patients’ expectation of the treatment outcome, unavailability of efficacious drugs, and the multifactorial and incompletely understood underlying pathophysiology. Currently, pharmacological treatment options target individual symptoms, such as abdominal pain, altered bowel habits, and bloating. In this review, we aimed to summarize the current and recent pharmacological treatment options in IBS-D, targeting the predominant gastrointestinal symptoms. Additionally, we proposed a pharmacological treatment algorithm which healthcare professionals could use when treating individual patients with IBS-D.

Irritable Bowel Syndrome with Diarrhea

2018 ◽  
Author(s):  
Judy Nee ◽  
Jacqueline L. Wolf
Keyword(s):  
Irritable Bowel Syndrome ◽  
Differential Diagnosis ◽  
Abdominal Pain ◽  
Treatment Options ◽  
Clinical Manifestations ◽  
Signs And Symptoms ◽  
Treatment Modalities ◽  
Dietary Advice ◽  
Emerging Therapies ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a complex, functional gastrointestinal condition characterized by abdominal pain and alteration in bowel habits without an organic cause. One of the subcategories of this disorder is IBS with diarrhea (IBS-D). Clinically, patients who present with more than 3 months of abdominal pain or discomfort associated with an increase in stool frequency and/or loose stool form are defined as having IBS-D. This review addresses IBS-D, detailing the epidemiology, etiology and genetics, pathophysiology and pathogenesis, diagnosis, clinical manifestations and physical examination findings, differential diagnosis, treatment, emerging therapies, complications, and prognosis. Figures show potential mechanisms and pathophysiology of IBS, IBS-D suspected by clinical assessment and Rome III criteria, pharmacologic and nonpharmacologic treatment options, potential mechanisms of action of probiotics, and potential treatment modalities. Tables list the Rome criteria for IBS, alarm signs and symptoms suggestive of alternative diagnoses, IBS criteria, differential diagnosis of IBS-D, dietary advice options for IBS-D, and alternative and emerging therapies in IBS-D. This review contains 5 highly rendered figures, 6 tables, and 99 references. 

scholarly journals Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile

2017 ◽  
Vol 10 ◽  
pp. 117955221772890 ◽  
Author(s):  
Kamesh Gupta ◽  
Harparam Singh Ghuman ◽  
Shivani Vijay Handa
Keyword(s):  
Irritable Bowel Syndrome ◽  
Mechanism Of Action ◽  
Symptomatic Relief ◽  
Treatment Options ◽  
Bacterial Overgrowth ◽  
Gastrointestinal Disorder ◽  
Small Intestinal Bacterial Overgrowth ◽  
Current Treatment ◽  
Predominant Type ◽  
Irritable Bowel

Background: Irritable bowel syndrome is classified as a functional gastrointestinal disorder with the primary symptom of abdominal pain in conjunction with bloating and bowel movement disorder. It affects up to 15% of the world’s population. Among its subtypes, the most common is diarrhoea predominant. However, the current treatment options for diarrhoea-predominant irritable bowel syndrome have had not very promising results; most, such as antispasmodics, only provide partial symptomatic relief. Treatment with antidepressants and alosetron (a 5HT3 antagonist) has shown the most promise to date. The latest drug to be approved for the treatment of irritable bowel syndrome-diarrhoea is rifaximin, which was approved in May 2015. It is a minimally absorbed antibiotic that is used to change the gut microbiota. Small intestinal bacterial overgrowth is one of the causes suggested for irritable bowel syndrome, particularly for the diarrhoea-predominant type. There are various methods for detecting bacterial overgrowth, the simplest of which is breath tests. Rifaximin has been shown to be of benefit to these patients. Purpose: The purpose of the study is to discuss the potential mechanism of action of rifaximin, a minimally absorbed antibiotic. In addition, we evaluate the various clinical trials undertaken to study the efficacy and safety profile of rifaximin.

Sign in / Sign up

Export Citation Format

Share Document